Top

Journal of Experimental & Clinical Cancer Research

Published in:

Open Access 01-12-2024 | Correction

Correction: RNA-binding protein RPS7 promotes hepatocellular carcinoma progression via LOXL2-dependent activation of ITGB1/FAK/SRC signaling

Authors: Yu-Jiao Zhou, Min-Li Yang, Xin He, Hui-Ying Gu, Ji-Hua Ren, Sheng-Tao Cheng, Zhou Fu, Zhen-Zhen Zhang, Juan Chen

Published in: Journal of Experimental & Clinical Cancer Research | Issue 1/2024

Excerpt

Correction: J Exp Clin Cancer Res 43, 45 (2024) …

Zhou YJ, Yang ML, He X, et al. RNA-binding protein RPS7 promotes hepatocellular carcinoma progression via LOXL2-dependent activation of ITGB1/FAK/SRC signaling. J Exp Clin Cancer Res. 2024;43:45. https://doi.org/10.1186/s13046-023-02929-1.CrossRefPubMedPubMedCentral

Title: Correction: RNA-binding protein RPS7 promotes hepatocellular carcinoma progression via LOXL2-dependent activation of ITGB1/FAK/SRC signaling
Authors: Yu-Jiao Zhou
Min-Li Yang
Xin He
Hui-Ying Gu
Ji-Hua Ren
Sheng-Tao Cheng
Zhou Fu
Zhen-Zhen Zhang
Juan Chen
Publication date: 01-12-2024
Publisher: BioMed Central
Published in: Journal of Experimental & Clinical Cancer Research / Issue 1/2024
Electronic ISSN: 1756-9966
DOI: https://doi.org/10.1186/s13046-024-02999-9

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 1/2024

The feedback loop of EFTUD2/c-MYC impedes chemotherapeutic efficacy by enhancing EFTUD2 transcription and stabilizing c-MYC protein in colorectal cancer

Exploring new frontiers: cell surface vimentin as an emerging marker for circulating tumor cells and a promising therapeutic target in advanced gastric Cancer

Unraveling the complexity of STAT3 in cancer: molecular understanding and drug discovery

CCAAT enhancer binding protein delta activates vesicle associated membrane protein 3 transcription to enhance chemoresistance and extracellular PD-L1 expression in triple-negative breast cancer

GPR65 sensing tumor-derived lactate induces HMGB1 release from TAM via the cAMP/PKA/CREB pathway to promote glioma progression

Targeting of focal adhesion kinase enhances the immunogenic cell death of PEGylated liposome doxorubicin to optimize therapeutic responses of immune checkpoint blockade

Keynote webinar | Spotlight on antibody–drug conjugates in cancer